Show simple item record

dc.contributor.authorSancho, Pen_US
dc.contributor.authorBarneda, Den_US
dc.contributor.authorHeeschen, Cen_US
dc.date.accessioned2016-09-26T11:23:12Z
dc.date.available2016-04-12en_US
dc.date.issued2016-06-14en_US
dc.date.submitted2016-09-21T13:55:02.614Z
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/15611
dc.description.abstractCancer cells adapt cellular metabolism to cope with their high proliferation rate. Instead of primarily using oxidative phosphorylation (OXPHOS), cancer cells use less efficient glycolysis for the production of ATP and building blocks (Warburg effect). However, tumours are not uniform, but rather functionally heterogeneous and harbour a subset of cancer cells with stemness features. Such cancer cells have the ability to repopulate the entire tumour and thus have been termed cancer stem cells (CSCs) or tumour-initiating cells (TICs). As opposed to differentiated bulk tumour cells relying on glycolysis, CSCs show a distinct metabolic phenotype that, depending on the cancer type, can be highly glycolytic or OXPHOS dependent. In either case, mitochondrial function is critical and takes centre stage in CSC functionality. Remaining controversies in this young and emerging research field may be related to CSC isolation techniques and/or the use of less suitable model systems. Still, the apparent dependence of CSCs on mitochondrial function, regardless of their primary metabolic phenotype, represents a previously unrecognised Achilles heel amendable for therapeutic intervention. Elimination of highly chemoresistant CSCs as the root of many cancers via inhibition of mitochondrial function bears the potential to prevent relapse from disease and thus improve patients' long-term outcome.en_US
dc.description.sponsorshipERC Advanced Investigator Grant (Pa-CSC 233460 to CH), the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 256974 (EPC-TM-NET to C.H.) and no 602783 (CAM-PaC to C.H.), the 2015 SU2C Lustgarten CRUK Pancreatic Cancer Dream Team Award (to CH), Pancreatic Cancer UK RIF2014_04 and RIF2015_03 (both to CH) and the Pancreatic Cancer Research Fund (to PS).en_US
dc.format.extent1305 - 1312en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofBr J Canceren_US
dc.subjectAnimalsen_US
dc.subjectCell Differentiationen_US
dc.subjectCell Proliferationen_US
dc.subjectGlycolysisen_US
dc.subjectHumansen_US
dc.subjectNeoplasmsen_US
dc.subjectNeoplastic Stem Cellsen_US
dc.subjectOxidative Phosphorylationen_US
dc.titleHallmarks of cancer stem cell metabolism.en_US
dc.typeArticle
dc.rights.holder(c) The Authors, 2016
dc.identifier.doi10.1038/bjc.2016.152en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/27219018en_US
pubs.issue12en_US
pubs.notesNo embargoen_US
pubs.publication-statusPublisheden_US
pubs.volume114en_US
dcterms.dateAccepted2016-04-21en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record